Eli Lilly (LLY)

Eli Lilly's key catalyst for 2027 could positively affect price action sooner than you think.

With volatility heating up, some investors may prefer the straightforward approach of the Vanguard Mega Cap Growth ETF.

Eli Lilly investors may be eyeing potential gains from the company’s annual dividend yield of 0.62% ($6.92 a year).

Global pharmaceutical company Eli Lilly (NYSE:LLY) will be reporting results this Wednesday morning. Here’s what investors should know. Eli Lilly beat analys...

Inspire Medical Systems (NYSE:INSP) reported second-quarter revenue of $200.6 million, down 7.6% from a year earlier, as coding and reimbursement disruptions continued to affect procedure volumes. The company said results exceeded its internal expectations for profitability and cash flow, prompting

The healthcare stock is up over 300% in five years and has a market cap of around $1 trillion.

XBI surged 76% in one year but carries triple the expense ratio and far steeper downside risk. Which fund matches your risk appetite?

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences and Uber Technologies are expected to have significant market moves based on their upcoming earnings reports.

Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

IBBQ posted the stronger return over the past year, but has also experienced much higher historical volatility than XLV.

And it will likely be the first company in the sector to get there.

PBE surged 41% in one year but endured a 35% drawdown, while XLV's diversified approach delivered steadier gains with half the volatility.

FHLC holds 334 positions versus IYH's 100, yet both delivered similar five-year returns despite their structural differences.

With the stock near a 5-year low, is it worth a look?

The global market for obesity drugs is soaring, yet Lilly has a dominant market share.

IHE's pharma-focused portfolio delivered higher returns over the past year, while XLV offers a broader healthcare focus with a much lower expense ratio.

FHLC's 0.08% expense ratio and market-cap approach delivered stronger returns, while RSPH's equal-weight strategy offers lower volatility and broader diversification across 60 holdings.

Wegovy and Zepbound makers Novo Nordisk and Eli Lilly faced pressure.

There are other reasons to pay attention to Viking Therapeutics.

PBE delivered the better return over the past year, but has experienced greater historical volatility. VHT's more diversified portfolio and rock-bottom fees offer investors a steadier, lower-cost option.

CNBC's Mad Money Lightning Round: Cramer says Astera Labs (ALAB) is a buy, but doesn't care for Rigetti Computing (RGTI). Eli Lilly (LLY) is a classic own, don't trade. MakeMyTrip (MMYT) coverage initiated with Buy rating.

But is that performance sustainable?

They may profit from the rapidly growing GLP-1 market in very different ways.